CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk.

ABSTRACT:

Background

Menopausal hormone therapy (MHT) use has been consistently associated with a decreased risk of colorectal cancer (CRC) in women. Our aim was to use a genome-wide gene-environment interaction analysis to identify genetic modifiers of CRC risk associated with use of MHT.

Methods

We included 10 835 postmenopausal women (5419 cases and 5416 controls) from 10 studies. We evaluated use of any MHT, oestrogen-only (E-only) and combined oestrogen-progestogen (E+P) hormone preparations. To test for multiplicative interactions, we applied the empirical Bayes (EB) test as well as the Wald test in conventional case-control logistic regression as primary tests. The Cocktail test was used as secondary test.

Results

The EB test identified a significant interaction between

SUBMITTER: Garcia-Albeniz X 

PROVIDER: S-EPMC4815813 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature